“We expect sales erosion driven by unfavorable pricing in The U.S., and generic launches particularly in The EU.”

In context

“it-risk profile. In inflammation, TestBio sales grew 52% year over year to nearly $1.5 billion for the full year. Taspire is well-positioned to reach more patients in The United States due to its differentiated TSLP mechanism that targets multiple inflammatory pathways driving severe uncontrolled asthma. Including in those with coexisting chronic rhinosinusitis with rhinosinusitis with nasal polyps, TestBiR substantially reduced the need for surgery in this population reinforcing its value in eosinophilic disease. TESSPIRE is now the leading therapy for new-to-brand patients amongst allergists in severe uncontrolled asthma. Fueled by strong prescriber confidence and continued expansion across respiratory specialties. Otezla sales increased 7% year over year to nearly $23 billion for 2026, We expect sales erosion driven by unfavorable pricing in The U.S., and generic launches particularly in The EU. Our innovative oncology portfolio, which includes BLINCYTO, INVELTRA, LUMICRAZ, VECTOBIX, KYPROLIS, ENDLATE, and XGEVA grew 11% year over year, generating $8.7 billion in full-year sales. Imdeltro delivered $627 million in full-year sales fueled by strong clinical conviction and rapid adoption across care settings. Over 1,600 U.S. Sites now administer IMDELTRA with the majority of doses provided in the community setting. Imdultra was granted full FDA approval in the fourth quarter, supported by compelling data from the Phase III DELPHY-three zero four trial. NCCN guidelines also recognize Imdeltra as the highest recommended therapy. And it has become the standard of care in the second-line setting. Reinforcing its leadership position in small cell lung cancer. BLINCYTO grew 28% year over”